The estimated Net Worth of Wagner M. Zago is at least $3.43 million dollars as of 2 August 2023. Wagner Zago owns over 4,000 units of Prothena plc stock worth over $83,720 and over the last 7 years he sold PRTA stock worth over $0. In addition, he makes $3,341,640 as Chief Scientific Officer at Prothena plc.
Sign up
Wagner Zago PRTA stock SEC Form 4 insiders trading
Wagner has made over 7 trades of the Prothena plc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 4,000 units of PRTA stock worth $48,600 on 2 August 2023.
The largest trade he's ever made was exercising 115,250 units of Prothena plc stock on 22 June 2021 worth over $2,052,603. On average, Wagner trades about 11,063 units every 133 days since 2017. As of 2 August 2023 he still owns at least 4,000 units of Prothena plc stock.
You can see the complete history of Wagner Zago stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wagner Zago biography
Dr. Wagner M. Zago Ph.D. serves as Chief Scientific Officer of the Company. Prior to that, since 2015, he was our Vice President, Head of Research. From 2012 to 2015, Dr. Zago was our Head of Pharmacology and Neuropathology. From 2006 to 2012, he held various scientific positions at Elan Pharmaceuticals, Inc, performing research aimed at developing new therapeutics for central nervous system disorders and inflammation. While in these positions, from 2009 to 2013, Dr. Zago also served as a Scientist at Janssen Alzheimer Immunotherapy, a Johnson & Johnson Company (a biopharmaceutical company). He earned his BS in Biomedicine from the Universidade Federal de Sao Paulo (Escola Paulista de Medicina), Brazil, and his M.S and PhD (both in Pharmacology) from the Universidade de Sao Paulo, Brazil, and was a Post-Doctoral Researcher at the University of California, San Diego and the Burnham Institute.
What is the salary of Wagner Zago?
As the Chief Scientific Officer of Prothena plc, the total compensation of Wagner Zago at Prothena plc is $3,341,640. There are no executives at Prothena plc getting paid more.
How old is Wagner Zago?
Wagner Zago is 47, he's been the Chief Scientific Officer of Prothena plc since 2017. There are 17 older and 6 younger executives at Prothena plc. The oldest executive at Prothena Corporation plc is Christopher Henney, 78, who is the Independent Director.
What's Wagner Zago's mailing address?
Wagner's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Insiders trading at Prothena plc
Over the last 12 years, insiders at Prothena plc have traded over $79,429,035 worth of Prothena plc stock and bought 2,987,732 units worth $75,619,043 . The most active insiders traders include Capital, Llc Eco R1, Co Plc Elan Corp Plc Elan S... et Helen Susan Kim. On average, Prothena plc executives and independent directors trade stock every 21 days with the average trade being worth of $946,769. The most recent stock trade was executed by Karin L Walker on 24 January 2024, trading 5,000 units of PRTA stock currently worth $67,650.
What does Prothena plc do?
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
What does Prothena plc's logo look like?
Complete history of Wagner Zago stock trades at Prothena plc
Prothena plc executives and stock owners
Prothena plc executives and other stock owners filed with the SEC include:
-
Wagner Zago,
Chief Scientific Officer -
Gene Kinney,
President, Chief Executive Officer, Director -
Michael Malecek,
Chief Legal Officer and Company Secretary -
Tran Nguyen,
Chief Financial Officer, Chief Operating Officer -
Carol Karp,
Chief Regulatory Officer -
Radhika Tripuraneni,
Chief Development Officer -
Dr. Gene G. Kinney Ph.D.,
Pres, CEO & Director -
Dr. Hideki Garren M.D., Ph.D.,
Chief Medical Officer -
Tran B. Nguyen M.B.A.,
CFO & Chief Strategy Officer -
Carol D. Karp,
Chief Regulatory Officer -
Michael J. Malecek,
Chief Legal Officer & Company Sec. -
Brandon S. Smith,
Chief Operating Officer -
Paula Cobb,
Independent Director -
Lars Ekman,
Independent Chairman of the Board -
Dennis Selkoe,
Independent Director -
Shane Cooke,
Independent Director -
Richard Collier,
Independent Director -
Christopher Henney,
Independent Director -
K. Anders Harfstrand,
Independent Director -
Brandon Smith,
Chief Business Officer -
Oleg Nodelman,
Independent Director -
Karin Walker,
Chief Accounting Officer, Controller -
Dr. Radhika Tripuraneni M.D., M.P.H.,
Chief Devel. Officer -
Dr. Hideki Garren,
Chief Medical Officer -
Dr. Radhika Tripuraneni M.P.H., M.D.,
Chief Devel. Officer -
Jennifer Zibuda,
Director of Investor Relations & Communication -
Dr. Wagner M. Zago,
Chief Scientific Officer -
Karin L. Walker CPA, CPA,
Chief Accounting Officer & Controller -
Sarah B. Noonberg,
Chief Medical Officer -
Arthur W Homan,
Chief Legal Officer -
Tara Nickerson,
Chief Business Officer -
Martin Koller,
Chief Medical Officer -
Capital, Llc Eco R1,
10% owner -
Sanjiv Patel,
-
Co Plc Elan Corp Plc Elan S...,
-
Dale B. Schenk,
President and CEO -
John Randall Fawcett,
Controller -
David B. Mc Ninch,
Chief Commercial Officer -
William H. Jr. Dunn,
-
Helen Susan Kim,
-
Daniel G Welch,
-
Hideki Garren,
Chief Medical Officer -
David A Ford,
Chief People Officer